Barinthus Biotherapeutics plc

Overview

• Clinical-stage biopharmaceutical company focused on antigen-specific immune tolerance therapies for autoimmune and inflammatory diseases.
• Core platform: SNAP-TI — self-assembling nanoparticles that deliver antigens in a tolerogenic context to shift T cell balance toward regulatory T cells (Treg) and away from pro-inflammatory Teff cells.
• Lead candidate: VTP-1000, designed to restore immune non-responsiveness to gluten in celiac disease; currently in a Phase 1 clinical program (AVALON).
• Legacy/early-stage programs: VTP-300 (HBV-based immunotherapy) and other viral-vector assets are being positioned for partnering.
• 2025 strategic refocus prioritized immunology and inflammation (I&I) indications, included a workforce reduction of approximately 65%, potential U.K. site closure, and measures to extend cash runway into 2027.
• Entered an all-stock merger agreement with Clywedog in September 2025 to form Topco, to be renamed Clywedog Therapeutics Holdings, Inc., expected to trade on Nasdaq under ticker CLYD; closing anticipated in Q2 2026.

Key programs and clinical development

VTP-1000 — Celiac disease (gluten antigen-specific tolerance)

• Platform: SNAP-TI with multiple gluten antigens plus an immunomodulator, delivered in nanoparticles to promote immune tolerance.
• Clinical program: AVALON Phase 1 (single ascending dose [SAD] followed by multiple ascending dose [MAD] with gluten challenge) to assess safety, tolerability, and pharmacology.
• December 2025 update: SAD enrolled 18 participants across three placebo-controlled cohorts; well tolerated with no treatment-related serious adverse events; dose-dependent pharmacology observed. MAD portion is ongoing; additional data expected in H2 2026.

VTP-300 — Chronic hepatitis B (legacy asset)

• Platform: Viral vectors (ChAdOx and MVA) encoding HBV genotype C antigens to induce disease-specific T cell responses.
• Clinical data: Phase 2 (HBV003) reported in 2025 showed meaningful reductions in HBsAg, including in subgroups with baseline HBsAg ≤200 IU/mL; reductions observed by Day 29 and sustained to Day 169. Some participants achieved HBsAg loss and a subset met criteria to discontinue NUC therapy. Treatment was generally well tolerated.
• Status: Deprioritized in CHB and available for partnership discussions.
• 2025 context: End-of-study data from AB-729/IM-PROVE II with Arbutus Biopharma were presented in 2025 and indicated potential for a functional cure in certain regimens.

Barinthus legacy assets (poised for partnering)

• VTP-300 (HBV)
• VTP-500 (MERS)
• VTP-850 (Prostate cancer)
• Strategy: Future development expected to be advanced by partners.

Collaborations, licensing and intellectual property

• IP position (as of March 6, 2026): Broad patent portfolio covering SNAP-TI, SNAP-CI, and star polymer technologies; in-licensed and co-owned families with Oxford University Innovation (OUI), NIH (CRADA/licensing-derived IP), and IMC.
• Patent term outlook: Multiple families with expiration windows generally between 2030 and 2043, subject to jurisdiction and potential extensions.
• Patent counts noted: one issued U.S. patent; twelve U.S. patent applications pending; seven issued foreign patents; sixty-one foreign patent applications pending.
• Product-specific IP: VTP-1000 patent family includes two pending U.S. applications, one pending European application, and nine pending foreign applications (anticipated expiration around 2043, excluding extensions).

License agreements and collaborations

• 2017 OUI License Agreement
  • Worldwide license for thermo-responsive adjuvant scaffolds and related technology; exclusive in field with restricted sublicensing.
  • Upfront £3,000; low-single-digit royalties on net sales; potential milestone payments up to £2.43 million; term tied to patent life or 20 years from agreement date; termination rights on uncured breach.
• NIH CRADA (2017, amended through 2021)
  • Collaborative research on Immunotherapeutic Nanoscaffolds (IMNs) including SNAP technologies; NIH retains government rights in CRADA IP; Barinthus/Avidea had option to exclusively license NIH inventions under the CRADA. CRADA expired February 23, 2025, with amendments extending scope through 2025.
• NIH License Agreement (2019)
  • Worldwide exclusive license under NIH patents related to SNAP-TI and SNAP-CI; sublicensing requires NIH consent; NIH retains government rights.
  • Upfront $20,000; low-single-digit royalties; potential milestone payments up to $3.24 million per licensed product; cited patent family expirations in the 2038–2042 range.
• Other history: Acquisition of Avidea Technologies and associated SNAP-TI IP in 2021; ongoing rights to certain CRADA-derived inventions and IMC patent families through arrangements with Barinthus Bio NA.

Regulatory and market exclusivity context

• Regulatory pathways follow standard U.S. FDA approaches (NDA/BLA), GCP/cGMP requirements, post-approval obligations, pediatric and orphan designations, and expedited programs (Fast Track, Breakthrough, Accelerated Approval, Priority Review) under evolving rules such as FDORA.
• Orphan drug designation can provide seven years of market exclusivity for qualifying indications; pediatric exclusivity and biologic/regulatory exclusivity considerations apply.
• Outside the U.S., regulatory oversight includes the EU Clinical Trials Regulation and comparable global frameworks relevant to IMNs and SNAP platforms.

Corporate developments and financial highlights

• 2025 strategic refocus concentrated the pipeline on I&I indications, deprioritized VTP-300 in CHB pending partner interactions, and sought partners for other viral-vector assets.
• Workforce and operations: Approximately 65% workforce reduction in 2025 and consolidation of operations to Germantown, Maryland; potential U.K. site closure.
• Cash runway extended into 2027.
• Merger with Clywedog announced September 2025: all-stock transaction to combine portfolios and create a broader clinical-stage company; post-merger name Clywedog Therapeutics Holdings, Inc., expected Nasdaq ticker CLYD; closing expected Q2 2026.
• 2025 payments to partners:
  • OUI: £59,360 paid in 2025 (difference between royalties paid and minimum royalty obligation under the 2017 OUI License Agreement).
  • NIH: $45,000 paid in 2025 (difference between royalties paid and minimum obligation; no NIH royalties disbursed as of March 6, 2026).
• VTP-1000 AVALON update (December 2025): SAD portion enrolled 18 participants across three placebo cohorts; well tolerated with dose-dependent pharmacology; MAD ongoing with gluten challenge; data expected H2 2026.

Bottom-line takeaway

Barinthus Biotherapeutics is a clinical-stage company developing antigen-specific immune tolerance therapies based on the SNAP-TI platform. Its lead asset, VTP-1000 for celiac disease, is in Phase 1, while viral-vector programs such as VTP-300 have been moved into legacy status and are being positioned for partnership. The company completed a strategic refocus in 2025 to concentrate on I&I indications, implemented operational consolidation, and announced a planned merger with Clywedog to create a broader clinical-stage enterprise. The company holds a multi-family patent portfolio in SNAP-related technologies through in-licenses and co-owned agreements.